中国临床药理学杂志Issue(4)：291-293,3.DOI:10.13699/j.cnki.1001-6821.2016.04.001
缬沙坦或贝那普利联合阿托伐他汀治疗慢性心力衰竭的临床研究
Clinical efficacy and safety of valsartan or benazepril combined with atorvastatin in the treatment of chronic cardiac failure
摘要
Abstract
Objective To evaluated the clinical efficacy and safety of valsartan or benazepril combined with atorvastatin in the treatment of chronic cardiac failure in elderly patients.Methods Eighty-six cases with chronic cardiac failure were recruited in this study and randomly divided into treatment group ( n =42 ) and control group ( n =44 ).Patients in treatment group were received valsartan 80 mg · d-1 orally plus atorvastatin 10 mg · d-1 orally, patients in control group received benazepril 10 mg · d-1 orally plus atorvastatin 10 mg · d-1 orally.The course was 3 months.After treatment , the clinical efficacy , serum level of brain natriuretic peptide and adverse event were compared between the two groups.Results The total clinical efficacy of treatment group and control group were 90.48% and 86.36% respectively with no statistical difference ( P>0.05 ).The serum level of brain natriuretic peptide sig-nificant decreased in the both groups ( P<0.05 ) after treatment.And the serum level of brain natriuretic peptide in treatment group was significant lower compared with that in control group after treatment ( P<0.05 ).There were no statistical difference on adverse drug reactions between two groups ( P>0.05 ).Conclusion The clinical efficacy and safety were not significantly different for valsartan or benazepril combined with atorvastatin in the treatment of chronic cardiac failure in elderly patients .关键词
慢性心力衰竭/缬沙坦/贝那普利/临床疗效/安全性Key words
chronic cardiac failure/leflunomide/glucocorticoid/clinical efficacy/safety分类
医药卫生引用本文复制引用
胡勇钧,唐哨勇,陈姣,黄晴,彭雄,彭定凤..缬沙坦或贝那普利联合阿托伐他汀治疗慢性心力衰竭的临床研究[J].中国临床药理学杂志,2016,(4):291-293,3.基金项目
武汉市卫生局临床科研基金资助项目 （）
